NCT00950859 - A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

January 31, 2015

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

GSK1349572 (Cohort I)

50 mg once daily

DRUG

GSK1349572 (Cohort II)

50 mg twice daily

Trial Locations (26)

13009

GSK Investigational Site, Marseille

20007

GSK Investigational Site, Washington D.C.

20127

GSK Investigational Site, Milan

27514

GSK Investigational Site, Chapel Hill

28029

GSK Investigational Site, Madrid

28209

GSK Investigational Site, Charlotte

32804

GSK Investigational Site, Orlando

33000

GSK Investigational Site, Bordeaux

33308

GSK Investigational Site, Fort Lauderdale

33316

GSK Investigational Site, Fort Lauderdale

34295

GSK Investigational Site, Montpellier

41013

GSK Investigational Site, Seville

69437

GSK Investigational Site, Lyon

75246

GSK Investigational Site, Dallas

75651

GSK Investigational Site, Paris

80220

GSK Investigational Site, Denver

85012

GSK Investigational Site, Phoenix

87505

GSK Investigational Site, Santa Fe

90813

GSK Investigational Site, Long Beach

94115

GSK Investigational Site, San Francisco

94275

GSK Investigational Site, Le Kremlin-Bicêtre

M5G 2N2

GSK Investigational Site, Toronto

H3G 1A4

GSK Investigational Site, Montreal

06202

GSK Investigational Site, Nice

08916

GSK Investigational Site, Badalona

08036

GSK Investigational Site, Barcelona